Overview

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant

Status:
Enrolling by invitation

Trial end date:
2022-04-30

Target enrollment:

Participant gender:

Summary

This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV negative recipient patients, with preemptive, interventional treatment with 12 weeks of commercially available DAA therapy to prevent HCV transmission upon transplantation.

Phase:

Phase 4

Details

Lead Sponsor:

Massachusetts General Hospital

Treatments:

Antiviral Agents
Sofosbuvir
Sofosbuvir-velpatasvir drug combination